Related Experiment Video
Updated: Jun 2, 2026
04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
Medical therapy for obesity.
Barham K Abu Dayyeh1, Lee M Kaplan
1Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Gastrointestinal Endoscopy Clinics of North America
|May 17, 2011
Summary
Obesity management needs personalized approaches, as broad strategies have fallen short. This review explores new drug therapies for obesity, focusing on approved and developing medications for effective patient care.
Area of Science:
- Medical Science
- Pharmacology
- Public Health
Background:
- Mild to moderate obesity affects more people and contributes significantly to public health burdens.
- Current high-risk and population-wide strategies for obesity management have proven insufficient.
- An individualized treatment approach is necessary for effective obesity management in a large patient population.
Purpose of the Study:
- To review advancements in pharmacologic therapies for obesity.
- To focus on currently approved obesity medications.
- To discuss obesity drugs in later stages of development.
Main Methods:
- Literature review of pharmacologic therapies for obesity.
- Analysis of approved drug treatments.
- Examination of drugs in clinical development pipelines.
Main Results:
- The review synthesizes information on various pharmacologic options for obesity.
- It highlights the current landscape of approved anti-obesity medications.
- It provides insights into emerging pharmacological treatments.
Conclusions:
- Pharmacologic therapies are crucial for managing obesity, especially with evolving treatment options.
- An individualized, drug-focused strategy may offer the most effective path for managing obesity in the broader population.
- Continued research and development in obesity pharmacotherapy are essential.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Behavior Therapy
Behavior therapy incorporates diverse techniques rooted in classical conditioning principles to address maladaptive behaviors and anxiety disorders. These methods aim to reduce avoidance behaviors, foster adaptive coping mechanisms, and alter associations between stimuli and responses, making them effective in a wide range of therapeutic contexts.
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...